Richard Bethell
Overview
Explore the profile of Richard Bethell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conaghan P, Bowes M, Kingsbury S, Brett A, Guillard G, Rizoska B, et al.
Ann Intern Med
. 2019 Dec;
172(2):86-95.
PMID: 31887743
Background: MIV-711 is a novel selective cathepsin K inhibitor with beneficial effects on bone and cartilage in preclinical osteoarthritis models. Objective: To evaluate the efficacy, safety, and tolerability of MIV-711...
2.
Bankar A, Siriwardena T, Rizoska B, Rydergard C, Kylefjord H, Rraklli V, et al.
Haematologica
. 2019 Dec;
106(2):574-579.
PMID: 31857370
No abstract available.
3.
Xu H, Colby-Germinario S, Quashie P, Bethell R, Wainberg M
Antimicrob Agents Chemother
. 2015 Mar;
59(6):3189-96.
PMID: 25779585
Compound A is a novel nucleotide-competing HIV-1 reverse transcriptase (RT) inhibitor (NcRTI) that selects for a unique W153L substitution that confers hypersusceptibility to tenofovir, while the K65R substitution in RT...
4.
Beaulieu P, Anderson P, Bethell R, Bos M, Bousquet Y, Brochu C, et al.
J Med Chem
. 2014 Nov;
57(23):10130-43.
PMID: 25393851
The development of interferon-free regimens for the treatment of chronic HCV infection constitutes a preferred option that is expected in the future to provide patients with improved efficacy, better tolerability,...
5.
Fader L, Malenfant E, Parisien M, Carson R, Bilodeau F, Landry S, et al.
ACS Med Chem Lett
. 2014 Jun;
5(4):422-7.
PMID: 24900852
An assay recapitulating the 3' processing activity of HIV-1 integrase (IN) was used to screen the Boehringer Ingelheim compound collection. Hit-to-lead and lead optimization beginning with compound 1 established the...
6.
Xu H, Colby-Germinario S, Oliveira M, Rajotte D, Bethell R, Wainberg M
Antimicrob Agents Chemother
. 2014 May;
58(8):4515-26.
PMID: 24867966
A W153L substitution in HIV-1 reverse transcriptase (RT) was recently identified by selection with a novel nucleotide-competing RT inhibitor (NcRTI) termed compound A that is a member of the benzo[4,5]furo[3,2,d]pyrimidin-2-one...
7.
Fenwick C, Amad M, Bailey M, Bethell R, Bos M, Bonneau P, et al.
Antimicrob Agents Chemother
. 2014 Mar;
58(6):3233-44.
PMID: 24663024
BI 224436 is an HIV-1 integrase inhibitor with effective antiviral activity that acts through a mechanism that is distinct from that of integrase strand transfer inhibitors (INSTIs). This 3-quinolineacetic acid...
8.
Berger K, Lagace L, Triki I, Cartier M, Marquis M, Lawetz C, et al.
Antimicrob Agents Chemother
. 2013 Jul;
57(10):4928-36.
PMID: 23877706
Faldaprevir (BI 201335) is a selective NS3/4A protease inhibitor under development for the treatment of chronic hepatitis C virus (HCV) infection. NS3/4A genotyping and NS3 protease phenotyping analyses were performed...
9.
Sturino C, Bousquet Y, James C, DeRoy P, Duplessis M, Edwards P, et al.
Bioorg Med Chem Lett
. 2013 May;
23(13):3967-75.
PMID: 23673016
Recently, a new class of HIV reverse transcriptase (HIV-RT) inhibitors has been reported. The novel mechanism of inhibition by this class involves competitive binding to the active site of the...
10.
James C, DeRoy P, Duplessis M, Edwards P, Halmos T, Minville J, et al.
Bioorg Med Chem Lett
. 2013 Apr;
23(9):2781-6.
PMID: 23545107
A HTS screen led to the identification of a benzofurano[3,2-d]pyrimidin-2-one core structure which upon further optimization resulted in 1 as a potent HIV-1 nucleotide competing reverse transcriptase inhibitor (NcRTI). Investigation...